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Objective. To develop a cost-eﬃcient method for identifying adverse drug events (ADEs) and medication errors (MEs) identiﬁed
using outpatient electronic medical records within ambulatory settings.
Design. Comparison of sensitivity and cost of ‘‘traditional’’ pharmacist based approach to identifying ADEs and MEs during a 4
month period with a tiered approach.
Results. The proportion of computer generated signals analyzed identiﬁed as ADEs were similar using the two approaches while
the number of MEs was nearly double with tiered reviews suggesting the same or better sensitivity. Traditional pharmacist review
cost $68.70 to detect an ADE and tiered approach cost only $42.40.
Conclusion. Tiered review of ADEs and MEs by personnel with increasing clinical capability is more cost-eﬃcient than phar-
macist review.
 2003 Elsevier Inc. All rights reserved.
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Adverse drug events (ADEs) are a common and
costly cause of morbidity. Johnson estimated that drug-
related problems are responsible for 199,000 deaths, 8
million hospitalizations, 17 million emergency depart-
ment visits, and 116 million extra doctor visits at a cost
exceeding $76 billion annually [1,2]. A majority of these
drug related problems are ADEs, some of which are due
to medical errors (MEs).
Although rates and types of ADEs in the inpatient
setting have been well characterized, there are few* Corresponding author. Fax: 1-317-630-6962.
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doi:10.1016/S1532-0464(03)00059-5studies in the outpatient setting [3]. These studies in-
cluded voluntary reporting by providers [4], provider
survey [5], patient survey [6,7], and chart review [7].
Brigham and Womens Medical Center applied com-
puter based ADE surveillance in the outpatient setting
[8,9]. Studies ascertaining MEs are especially rare in the
adult outpatient population, except for a few studies in
the elderly [10].
Characterizing ADEs in the outpatient setting is
more diﬃcult than the inpatient setting because the
data are more fragmented and spread over longer,
disconnected time periods which increases the diﬃculty
and expense. In outpatient settings where an integrated
outpatient electronic medical record system is used,
there may be suﬃcient longitudinal data to determine
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scription and symptoms or other data that could signal
possible ADEs. Methods are needed to identify events
that could represent ADEs and to determine whether
an ADE has occurred. While a computer can rapidly
screen large numbers of encounters to ﬁnd candidate
ADEs and MEs, programs are not yet sophisticated
enough to determine whether an ADE or MEs has
truly occurred. In addition, the computer can augment
the human review process by assembling much of the
data needed but adjudicating a candidate event still
requires a human review process that is labor intensive
and expensive.
As part of a larger study, we have been studying
methods of ADE and ME identiﬁcation using electronic
medical records and human review at two health care
systems. A traditional, pharmacist based review process
was used at one site while a tiered approach—using tiers
or layers of personnel of varying expertise—was used at
the other. The tiered approach was implemented be-
cause we believed that preliminary review of records by
capable trained personnel who have lower salaries than
clinicians would reduce the amount of clinician time
required and reduce the overall cost of ADE review.
The purpose of this report is to describe a process of
ADE and ME identiﬁcation and compare review of
ADEs and MEs by the two methods of review.2. Methods
2.1. Patients and study sites
Patients eligible for inclusion in this study were those
18 years of age or older with outpatient appointments at
ambulatory care clinics during a four month period
(February 1, 2001 to May 31, 2001 for Indianapolis and
January 15, 2001 and May 15, 2001 for Boston). The
Indiana University Institutional Review Board and
Brigham and Womens Hospital Human Research
Committee approved the study.
The Indianapolis study site included 22 ambulatory
clinics from Wishard Health Services, an inner-city ac-
ademic health system aﬃliated with the Indiana Uni-
versity School of Medicine. For the past 3.5–5 years,
these clinics have used an online order entry system
called the Medical Gopher [11], whose data is captured
and stored in a retrievable format within the Regenstrief
Medical Record System [12]. Data are retrieved using a
programming language called CARE [13].
The Boston study site was Brigham and Womens
Medical Center, an urban tertiary academic medical
center, supported by the Brigham Integrated Computer
System [14]. Data are retrieved using the Cache lan-
guage. They selected 11 ambulatory clinics to include in
the study.2.2. ADE and ME deﬁnition and ascertainment
An ADE is harm associated with a drug. A ME is an
error in the medication use process including the pre-
scribing, transcribing, administering, and monitoring
steps [16]. If an event is associated with an ADE and
ME it is an ADE/ME.
Because non-clinicians performed the ﬁrst level of
review in the tiered method, we developed speciﬁc
guidance for identifying ADEs and MEs rather than
relying on the pharmacists judgment and experience.
Previous studies have deﬁned ADEs as injury due to
drug [3,8]. We decided to use the word harm rather than
injury because the data analysts (non-clinician reviewers)
thought injury to be an accident such as a broken bone
from falling, rather than symptoms such as nausea and
vomiting from taking a drug. ADEs are deﬁned as harm
associated with a drug which is often associated with
symptoms, and the data analysts could be trained to
identify those speciﬁc symptoms. For the data analysts
review, we deﬁned harm as documented new symptoms
or increase in the severity of previously documented
symptoms occurring after the ﬁrst prescription date, a
drug allergy, a new diagnosis suggesting harm from the
drug, or the drug discontinuation. In a few cases, we
assumed abnormal laboratory values caused harm even
if symptoms were not explicitly documented. Processing
MEs was more diﬃcult for the data analysts because not
all MEs result in harm. For the purposes of MEs, signals
were divided into four groups. Each signal set had a
series of questions associated with it to help guide the
data manager on how the signals within the set should
be processed. The questions used for signal sets are listed
in Appendix A.
One of the most valuable outcomes of data analysts
review tier was to exclude cases that were clearly not
ADEs. Examples of cases that would be excluded by
data analysts include when the drug was discontinued
before the onset or worsening of symptoms, a drug level
was elevated but there were not any symptoms or an
elevated laboratory value that return to normal despite
an increase in the drugs dosage. When there were
doubts about how to evaluate a case or whenever harm
was found, the case was referred to the next tier level of
increased knowledge for further processing. In sum-
mary, for a case to be classiﬁed as an ADE, harm must
have occurred, the drug must have been prescribed, and
the drug must be causally and temporally associated
with the medication.
2.3. System description
An expert panel, which drew on rules used in Wis-
hard Health Services and Brighams and Womens
Hospitals previous inpatient and outpatient ADE
studies, developed the 122 criteria for our study [8,15].
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we used to create the list of cases or candidate ADEs,
which we call signals (Appendix A). We referred to theTable 1
Examples of signal classes, criteria, groups, and associated symptoms
Signal class name Drug names Data an
process
Oral candidiasis Oral nystatin or clotrimazole
troches
Group
Exclude
NSAIDs & Hyperkalemia
(K > 5:5meq/L)
Ibuprofen; indomethacin;
ketoprofen; naproxen;
naproxen sodium; tolmentin;
oxaprozin; sulindac;
piroxicam; etodolac; mefemic
acid; nabumetone;
fenoprofen; choline
magnesium trisalicylate;
meclofemate; diclofenac;
ﬂurbiprofen; diﬂuinsal
Group
ME, po
exclude
Female receiving
ﬁnasteride
Finasteride Group
Sucralfate and PPI
(patient receiving
sucralfate and 1
medication from List A)
Sucralfate AND one med
from List A: esomeprazole;
lansoprazole; omeprazole;
pantoprazole; rabeprazole
Group
ME, po
The processing groups correspond to the rules the data analysts applied
Fig. 1. Example database form used to manage information from signals. Dat
whenever possible. Other information was entered into the form by human rev
provided the work list since is provided ready access to the review status ofcollection of signals generated by a single criterion as a
‘‘signal class’’ (Table 1). For example, one signal class
was a prescription for furosemide and a serum potas-alyst
ing group
Signal speciﬁc symptoms
2: (ADE,
)
Oral pain; mouth ulcers or sores, whitish-yellow
coated tongue, furry tongue
4: (ADE, ADE/
tential ADE,
d)
Elevated potassium; weakness, parathesias,
twitchy muscles, ﬂaccid paralysis, diarrhea,
arrhythmias
1: (ADE) Pregnancy risk factor: X, Counterindicated in
lactation, hirtuism
3: (ADE, ADE/
tential ADE)
Little or no eﬀect therapeutic eﬀect (gastric ulcer
may not heal, dyspepsia may continue)
when processing the signals (Appendix A).
a was downloaded into the database from the electronic medical record
iewers at all levels of the tiered review process. In addition the database
the signals and allowed them to be sub-categorized by signals.
Fig. 2. Tiered review ‘‘pyramid’’. Signals are identiﬁed from the elec-
tronic medical record by computer queries. Some signals are excluded
and data is added to signals that are not excluded by data managers
who have little clinical background. A nurse reviews the signals that
were not excluded and only the signals that have deeper clinical issues
require the registered pharmacists (RPh) attention.
Fig. 3. Signal volumes in the tiered review method. In the traditional
pharmacist review method, all 8,078 signals analyzed by the data an-
alysts would require pharmacist review. In the tiered review method,
the number of signals requiring review at each level decreases.
C. Hope et al. / Journal of Biomedical Informatics 36 (2003) 92–98 95sium level <3.0 meq/L. We used the queries to identify
signals or cases resulting from care during a four month
period, removed all duplicate signals we found and
randomly sampled the signals for review. We developed
a computer program to remove all but one of the signals
that resulted from a single clinical evaluation. The
program eliminated duplicate signals from the same
patient and signal class that had the same drug and drug
date or laboratory test and laboratory test date. Data
analysts also eliminated a few duplicates. In those cases
that required more clinical insight, the nurse and phar-
macist eliminated duplicates. The randomly selected
signals were imported into a database from which Mi-
crosoft Access forms (Fig. 1) were populated to enable
online review and adjudication of signals. The database
facilitated communication between the reviewers in the
tiers as well. All these steps were similar for both tiered
review and pharmacist review. At both sites, pharma-
cists consulted physicians as necessary.
Pharmacist review is a simple process. A pharmacist
reviews the patients chart looking for values for labo-
ratory tests, ﬁndings from procedures, and drug histo-
ries and decides how the signal should be classiﬁed based
on their judgment and experience. The rate limiting step
in this process is the number of pharmacists, the number
of charts that can be retrieved and the length of time
required to review a chart. In contrast, tiered review is a
more complicated process that is designed to reduce the
dependence of the availability of pharmacists time.
Tiered review had four levels: computer, data analysts,
nurse, and pharmacist or physician (Fig. 2). The review
can be visualized as a pyramid with fewer signals for
analysis by reviewers and increasing levels of clinical
training for tiers closer to the top. The ﬁrst tier is
computer identiﬁcation of signals using demographic
and administrative data, laboratory reports, progress
notes, prescription records, ICD-9 codes, diagnoses,
diagnostic procedures, discharge summaries, and other
clinical information. This step was the same at India-
napolis and Boston study sites. The second tier is data
analyst review. Its primary function was to exclude
signals that do not meet speciﬁc criteria, reducing the
number of signals that had to be reviewed at the third
and fourth tier. While the data analysts were not clini-
cally trained, they had college degrees and had been
working in the healthcare ﬁeld for several years. The
third tier consisted of adjudication by the study nurse.
The nurse reviewed the patients medical records; then
used clinical judgment to classify events, exclude signals,
or mark possible ADEs or MEs for further review and
send them to the fourth or pharmacist tier. Any par-
ticular insights or problems with signals were also doc-
umented. The fourth and ﬁnal tier involved adjudication
by the study pharmacist with consultation with physi-
cians as needed. Because of the previous support and
review by the data analysts and nurse, the pharmacistreceived the fewest number of signals and made the ﬁnal
classiﬁcations of signals as ADEs or MEs. The ﬂow of
signals through tiered review is illustrated in Fig. 3.
Nurses and pharmacists adjudicated MEs. For a
signal to be classiﬁed as a ME the drug must have been
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predictable adverse outcome under the patient speciﬁc
conditions. If the patient taking carbamazepine had
several toxic carbamazepine levels and no dose adjust-
ment was made, this signal was classiﬁed as an ME. If
symptoms occurred, it would be classiﬁed as an ADE/
ME and if no symptoms occurred it would be classiﬁed
as a potential ADE. A signal was classiﬁed as a potential
ADE/ME when the potential for an ADE was present,
but due to an intervention or unusual circumstance the
patient was not harmed. We did not classify use of a
medication that was likely to cause symptoms when a
good alternative was not available as an ME. All signals
were classiﬁed as either excluded, ADEs, ADE/MEs,
and potential ADE/MEs.
We continuously trained the data analysts in order to
improve their ability to accurately classify signals. They
initially received group training to introduce the use of
the database and sample cases. Each data analyst was
then assigned a group of signal classes to review and
received individual training about the speciﬁc issues for
their signal classes. For quality assurance purposes,
about 10% of the data analysts work was reviewed by a
nurse and/or pharmacist and further training was
available as needed. If the data analysts and nurse had
questions, they electronically passed the signal on to the
next higher tier for further review. The pharmacist had
assistance from other experienced pharmacists and
physicians.Table 2
Demographics of electronically searched population
Brigham and Women
Total number of visits, n 54,679
Total number of unique patients, n 33,202
Gender*: females n (%) 24,193 (73%)
Race*: black n (%) 4723 (14.2%)
Hispanic 3303 (10.0%)
White 12,037 (36.3%)
Other 985 (2.9%)
Unanswered 12,154 (36.6%)
Age* (years standard deviations) 47.5 16.8
Numbers and percentages are based on the total number of patients.
Table 3
Time and cost comparison of personnel to review signals—while the pharmac
to review every signal while in the tiered review system, and they reviewed l
Tiered review method
Salary ($/h) Time (min/signal)
Training costs
Data analyst 13.62 17
Nurse 16.43 15
Pharmacist 36.91 23
Total
The cost per ADE identiﬁed is $ 2468.70 with the pharmacist review me2.4. Cost comparison
We compared the time and costs of classifying ADEs
between tiered review and pharmacist review. In order to
estimate the time required bydata analysts, theymanually
tracked the time they spent processing signals and then
computed the mean time per signal. For pharmacist and
nurse review, the mean time per signal was based on the
time that it took to analyze four signals. The time required
per signal for the pharmacist in the pharmacist review
method was determined by recording the time required to
analyze four signals from the point of computer selection
to their classiﬁcation or exclusion. We obtained national
salary rates including beneﬁts for pharmacists, licensed
nurses and data analysts from www.salaryexpert.com
(accessed 7 February 2003) and computed hourly rates
assuming 1920 h annually.
We estimated total costs by multiplying the time per
signal by an hourly rate and computed the cost per ADE
by simple division. For the tiered review method, there
were also training, oversight and reporting costs that we
included. We did not include overhead cost allocations
so the actual costs will be higher but they would not
change the relative values.
2.5. Data analysis
In order to verify that the two review methods were
equivalent, we compared the positive predictive valuess medical center Wishard health services
38,731
19,426
13,176 (67.8%)
9967 (51.7%)
542 (2.8%)
8321 (43.2%)
268 (1.4%)
158 (0.8%)
54.5 14.9
ist took only slightly longer in the pharmacist review method, they had
ess than 1%
Pharmacist review method
Cost Time (min/signal) Cost
$4716
$8800
$8905
$185 26 $44,580
$22,606 $44,580
thod and $ 2442.40 with the tiered review method.
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and the pharmacist review using the v2 test.3. Results
At the Indianapolis site 5824 signals were identiﬁed
by 84 of the 126 ADE signal classes. No signals resulted
from the other 42 criteria. At the Boston site, 2492 sig-
nals resulted from 69 of the signal classes. The phar-
macist reviewed 1222 of these signals and eliminated 69
signals as duplication of the same event. The patient
populations (Table 2) diﬀered primarily in the propor-
tion of Afro-Americans.
We identiﬁed 242 and 535 ADEs and 104 and 562
MEs at the Boston and Indianapolis sites respectively.
The positive predictive value of a signal for ADEs was
10.2 and 9.6% for the two sites (p ¼ 0:36) and for MEs
was 4.4 and 10.0% for the two sites (p < 0:001).
Table 3 compares the estimated costs of the two ap-
proaches. The cost per ADE identiﬁed is $68.70 with the
pharmacist review method and $42.40 for the tiered re-
view method.4. Discussion
Organizations that want to improve the safety of the
care they deliver must be able to assess the number of
ADEs and MEs. Even when computerized screening for
adverse events is used, human review is necessary to
determine which signals identiﬁed by the computer
correspond to ADEs and MEs. The cost of performing
this review can be reduced by using a tiered review
process.
Even when a data analyst was unable to eliminate a
signal, they ﬁlled in portions of the form, such as the
patients drugs and allergies, reducing work for higher
salaried clinicians. Since the data analysts initial learn-
ing period was included in the calculation, the data
analysts average time to process a signal is conservative.
The fact that the PPVs were similar between the two
sites for ADEs and higher in Indianapolis for MEs
suggests that the tiered review process was just as sen-
sitive for detecting ADEs and MEs as the pharmacist
review process. We attribute the higher PPVs for MEs
found in Indianapolis to local diﬀerences in documen-
tation and interpretation of MEs. The higher PPV for
the tiered system suggests that it is at least as sensitive
for detecting these important events.
Because the review method (tiered or pharmacist) is
confounded with sites which have diﬀerent populations
and electronic medical records, we cannot be sure that
the diﬀerences are completely attributable to the meth-
od. In addition, the methods we used to measure the
time for various steps in the review process were notprecise but this should make little diﬀerence because of
the number of signal reviewed.5. Conclusion
A tiered review approach is more cost-eﬃcient
method than traditional pharmacist review for mea-
suring the rates of ADEs and MEs, which is a key
step in being able to reduce them. This approach
maintains sensitivity for identifying ADEs and MEs.
Even with the lower cost of the tiered review ap-
proach, ﬁnding ADEs will be cost prohibitive for
many organizations.Acknowledgments
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and technical programming.Appendix A. Signal processing guide for data analysts
Each signal was assigned to a group based on the
characteristics of the signal. The data analysts used the
speciﬁc directions for the group in order to guide their
analysis of the signals.
Abbreviations used in Appendix A: ADE, adverse
drug event; ADE/ME, adverse drug event and medica-
tion error; PADE, possible ADE, a ME that could have
caused possible harm occurred, but no harm occurred in
this case.
Group 1: ADE/(ADE/ME)
1. If Harm is not present, ﬁll in Drug/Lab and Allergies
tabs.
2. If Harm is present, ﬁll in Drug/Lab, Allergies, ADE
and (other) tabs.
Group 2: PADE/Exclude
1. Is Harm present?
2. Does Harm/Lab occur after Drug? (For antidote
substitute for ‘‘before’’.) If No, exclude.
3. If Harm is not present, ﬁll in Drug/Lab and Allergies
tabs.
4. If Harm is present, ﬁll in Drug/Lab, Allergies, ADE
and (other) tabs.
Group 3: ADE/(ADE/ME)/Exclude
1. Does Drug occur? If No, exclude.
2. Is Harm present?
3. Does Harm/Lab occur after Drug? (For antidote sub-
stitute for ‘‘before’’.) If No, exclude.
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tabs.
5. If Harm is present, ﬁll in Drug/Lab, Allergies, ADE
and (other) tabs.
Group 4: ADE/(ADE/ME)/PADE/Exclude
1. Does Drug occur? If No, exclude.
2. Is Harm present?
3. Does Harm/Lab occur after Drug? (For antidote sub-
stitute for ‘‘before’’.) If No, exclude.
4. If Harm is not present, ﬁll in Drug/Lab and Allergies
tabs.
5. If Harm is present, ﬁll in Drug/Lab, Allergies, ADE
and (other) tabs.References
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